BR9813508A - Membrane-associated viral replication inhibition - Google Patents

Membrane-associated viral replication inhibition

Info

Publication number
BR9813508A
BR9813508A BR9813508-2A BR9813508A BR9813508A BR 9813508 A BR9813508 A BR 9813508A BR 9813508 A BR9813508 A BR 9813508A BR 9813508 A BR9813508 A BR 9813508A
Authority
BR
Brazil
Prior art keywords
membrane
viral replication
replication inhibition
associated viral
compounds
Prior art date
Application number
BR9813508-2A
Other languages
Portuguese (pt)
Inventor
Timothy M Block
Raymond A Dwek
Anand Metha
Frances Platt
Terry D Butters
Nicole Zitzmann
Original Assignee
Univ Oxford
Univ Jefferson
Blumberg Baruch S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford, Univ Jefferson, Blumberg Baruch S filed Critical Univ Oxford
Publication of BR9813508A publication Critical patent/BR9813508A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Patente de Invenção: <B>"INIBIçãO DE REPLICAçãO VIRAL ASSOCIADA COM MEMBRANA"<D>. Processos para inibir a morfogênese de vírus de crescimento de membrana de célula hospedeira e infecções causadas assim usando compostos que inibem as enzimas glucosidase ou glucosiltransferase de célula hospedeira. Os processos para o tratamento de doenças de armazenamento de lipídeos usando compostos que inibem as enzimas glucosiltransferase.Invention Patent: <B> "VIRAL REPLICATION INHIBITION ASSOCIATED WITH MEMBRANE" <D>. Processes for inhibiting the morphogenesis of host cell membrane growth viruses and infections thus caused using compounds that inhibit the host cell glucosidase or glucosyltransferase enzymes. Processes for the treatment of lipid storage diseases using compounds that inhibit glucosyltransferase enzymes.

BR9813508-2A 1997-12-11 1998-12-10 Membrane-associated viral replication inhibition BR9813508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6924597P 1997-12-11 1997-12-11
PCT/US1998/026241 WO1999029321A1 (en) 1997-12-11 1998-12-10 Inhibition of membrane-associated viral replication

Publications (1)

Publication Number Publication Date
BR9813508A true BR9813508A (en) 2000-10-03

Family

ID=22087673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813508-2A BR9813508A (en) 1997-12-11 1998-12-10 Membrane-associated viral replication inhibition

Country Status (9)

Country Link
US (1) US6465487B1 (en)
EP (1) EP1037636A4 (en)
JP (1) JP2001525367A (en)
KR (1) KR20010033028A (en)
CN (1) CN1290168A (en)
AU (1) AU761748B2 (en)
BR (1) BR9813508A (en)
CA (1) CA2312423A1 (en)
WO (1) WO1999029321A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
EP1165080A2 (en) * 1999-02-12 2002-01-02 G.D. SEARLE &amp; CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6515028B1 (en) 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
AU1840101A (en) * 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US20050119310A1 (en) * 2000-02-14 2005-06-02 Mueller Richard A. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
GB0110832D0 (en) * 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2004155777A (en) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Therapeutic agent for chronic hepatitis c
US20060058350A1 (en) * 2002-12-26 2006-03-16 Carna Biosciences, Inc. Alkynyl-substituted azasugar derivative and drug containing the same as the active ingredient
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
JP2008509902A (en) * 2004-08-13 2008-04-03 ミジェニックス インコーポレイテッド Compositions and methods for treating or preventing Hepadnaviridae infection
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US7919521B2 (en) * 2005-12-05 2011-04-05 Academia Sinica Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
US20090275499A1 (en) * 2008-02-29 2009-11-05 Marie Flamand Nonstructural protein ns1 as a novel therapeutic target against flaviviruses
JP2011518124A (en) * 2008-03-26 2011-06-23 ユニバーシティ・オブ・オックスフォード Endoplasmic reticulum targeting liposome
CN102655746B (en) * 2009-02-23 2016-08-03 联合治疗公司 Iminosugar and the method for the treatment of viral disease
KR101787434B1 (en) * 2009-02-24 2017-11-15 유나이티드 세러퓨틱스 코오포레이션 Iminosugars and methods of treating arenaviral infections
KR20120059447A (en) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 Cholesterol level lowering liposomes
US8426445B2 (en) * 2009-06-12 2013-04-23 United Therapeutics Corporation Iminosugars and methods of treating bunyaviral and togaviral diseases
KR101459530B1 (en) * 2009-09-04 2014-11-07 유나이티드 세러퓨틱스 코오포레이션 Methods of treating poxviral infections
JP5653438B2 (en) * 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション Treatment of orthomyxovirus infection
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (en) 2011-10-21 2014-11-28 Эббви Инк. COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV
CA2875975A1 (en) 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
EP3046558B1 (en) 2013-09-16 2019-08-14 Emergent Virology LLC Deoxynojirimycin derivatives and methods of their using
BR112017008898B1 (en) 2014-11-05 2022-11-29 Emergent Virology Llc IMINOSUGAR COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES TO TREAT VIRAL DISEASES
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
KR20190104524A (en) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 Treatment method of sugar accumulation disease
KR102600115B1 (en) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 Composition for treating fibrosis
EP3768690A4 (en) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2834122A1 (en) 1978-08-03 1980-02-14 Bayer Ag METHOD FOR PRODUCING 6-AMINO-6-DESOXY-L-SORBOSE
DE2853573A1 (en) 1978-12-12 1980-07-03 Bayer Ag PREPARATION OF N-SUBSTITUTED DERIVATIVES OF L-DESOXYNOJIRIMYCIN
FR2472015A1 (en) 1979-12-21 1981-06-26 Beghin Say Sa ENZYMES IMMOBILIZED ON A SOLID SUPPORT
DE3650377T2 (en) 1985-12-23 1996-02-22 Hutchinson Fred Cancer Res REGULATION OF RETROVIRAL REPLICATION, INFECTION AND PATHOGENESIS.
DE3611841A1 (en) 1986-04-09 1987-10-15 Bayer Ag METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES
ZA883925B (en) * 1987-06-08 1989-02-22 Merrell Dow Pharma Inhibitors of glycoprotein processing having anti-retroviral activity
EP0350012A3 (en) * 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
US5003072A (en) * 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
ATE135346T1 (en) 1988-11-03 1996-03-15 Searle & Co DIDEOXY-L-ARABINITOL DERIVATIVES AS ANTIVIRUS COMPOUNDS
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5043273A (en) 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
DE4009561A1 (en) * 1990-03-24 1991-09-26 Bayer Ag New anti-retroviral desoxy:nojirimycin derivs.
DK0527815T3 (en) 1990-04-06 2000-11-06 Genelabs Tech Inc Hepatitis C virus epitope
US5091418A (en) 1990-09-28 1992-02-25 Bristol-Myers Squibb Company Novel alpha-glucosidase inhibitor, pradimicin Q
JPH0543545A (en) * 1991-08-15 1993-02-23 Meiji Seika Kaisha Ltd New aza-saccharide derivative
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
WO1995022975A1 (en) * 1994-02-25 1995-08-31 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
ATE295732T1 (en) * 1997-02-14 2005-06-15 Searle Llc USE OF N-SUBSTITUTED 1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY OF INFECTIONS CAUSED BY HEPATITIS VIRUS
AU753336B2 (en) 1997-11-10 2002-10-17 G.D. Searle & Co. Use of alkylated iminosugars to treat multidrug resistance
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof

Also Published As

Publication number Publication date
EP1037636A4 (en) 2004-08-18
EP1037636A1 (en) 2000-09-27
KR20010033028A (en) 2001-04-25
AU761748B2 (en) 2003-06-12
WO1999029321A1 (en) 1999-06-17
WO1999029321A9 (en) 1999-09-16
AU1721599A (en) 1999-06-28
CA2312423A1 (en) 1999-06-17
JP2001525367A (en) 2001-12-11
US6465487B1 (en) 2002-10-15
CN1290168A (en) 2001-04-04

Similar Documents

Publication Publication Date Title
BR9813508A (en) Membrane-associated viral replication inhibition
BR9807876A (en) Heterocyclic compounds and their use for inhibition of beta-amyloid peptide
BR9908280A (en) Phospholipase enzyme inhibitors
BR9610390A (en) The use of a thienotriazolodiazepine to increase levels of apoliprotein a-i
CO4520286A1 (en) PROCEDURE FOR PREPARING 1- (2-DEXESOXY-2, 2-DIFLUORO-D-RIBOFURANOSIL) -4-AMINOPYRIMIDIN-2-ONA
DE69837809D1 (en) APOLIPOPROTEIN A-I AGONISTS AND THEIR USE FOR THE TREATMENT OF DISLIPIDEMIC ILLNESSES
BR9714517A (en) Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising them and processes to inhibit beta-amyloid peptide release and / or its synthesis by using such compounds
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
EA199800184A1 (en) Benzimidazole compounds
BR0313371A (en) Compound, use of a compound and disease treatment method
TR199800759T2 (en) Protein Kinase C Inhibitor.
MX9207449A (en) INHIBITORS OF THE PROTEOLYTIC ENZYME DERIVED FROM SACARINE.
BR0111913A (en) Gabapentin analogs for sleep disorders
BR9713338A (en) Benzonaphyridines as bronchial therapeutics.
BR9910573A (en) Antipicornoviral compounds, preparation and use thereof
BR0315662A (en) 1- (4-Benzyl-piperazin-1-yl) -3-phenyl-propenone derivatives
EE04685B1 (en) The rate-controlling membrane or matrix of the drug
IT1295933B1 (en) 2- (2&#39;-HYDROXYPHENYL) BENZOTHRIAZOLS AND PROCEDURE FOR THEIR PREPARATION
BR9909638A (en) Biocidal composition stable to sunlight-ultraviolet, and process of inhibition of microbial growth in an aqueous system
BR0013765A (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazol-2-one and its use as a lipase inhibitor
DK0866711T3 (en) Use of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide for the preparation of a pharmaceutical composition for the prevention of sleep apnea
BR9714049A (en) Imidazopyridazines
BR9814188A (en) &#34;5-ht1f agonists&#34;
BR9909237A (en) Farnesyl-protein transferase inhibitors
AR005549A1 (en) DERIVATIVES OF 1-PIRAZOL-3-ILETIL-4-INDOL-3-ILPIPERIDINA, A PROCEDURE FOR PREPARING THEM, MEDICINES AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, A PROCEDURE FOR PREPARING THE PHARMACEUTICAL PREPARATIONS AND USE OF THE SAME MEDICINAL PREPARATIONS FOR THE PREPARATIONS

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.